NCT06610227View on ClinicalTrials.gov

A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

SapRNA™-MICA/B Tumor Vaccine

patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively

Trial Locations (1)

100021

National Cancer Center, Beijing

All Listed Sponsors

lead

NING LI

OTHER